Journal ArticleDOI
Chemotherapy of trypanosomiases and leishmaniasis
Reads0
Chats0
TLDR
Financial constraints continue to represent a major hurdle to drug development, however, the appearance of not-for-profit product-development partnerships offers a new paradigm for bringing new drugs to patients.About:
This article is published in Trends in Parasitology.The article was published on 2005-11-01. It has received 380 citations till now. The article focuses on the topics: Drug development.read more
Citations
More filters
Journal ArticleDOI
Control of Neglected Tropical Diseases
Peter J. Hotez,David H. Molyneux,Alan Fenwick,Jacob Kumaresan,Sonia Ehrlich Sachs,Jeffrey D. Sachs,Lorenzo Savioli +6 more
TL;DR: In addition to malaria, tuberculosis, and human immunodeficiency virus infection, several other infectious diseases are associated with substantial morbidity and mortality as discussed by the authors, in particular 13 tropical diseases that cause disabilities such as blindness and heart failure.
Journal ArticleDOI
Control of neglected tropical diseases.
Clare Huppatz,David N Durrheim +1 more
TL;DR: From the Sabin Vaccine Institute, and George Washington University, Washington, DC (P.J.H.Hotez, M.E.S., J.D.S.), this work was funded by the National Institutes of Health.
Journal ArticleDOI
Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches.
TL;DR: A critical review of the development of specific chemotherapeutic approaches for the management of American Trypanosomiasis or Chagas disease is presented, and the most promising approaches are ergosterol biosynthesis inhibitors such as posaconazole and ravuconazole.
Journal ArticleDOI
Recent advances in leishmaniasis treatment.
Tatiana Shioji Tiuman,Adriana Oliveira dos Santos,Tânia Ueda-Nakamura,Benedito Prado Dias Filho,Celso Vataru Nakamura +4 more
TL;DR: This review describes the arsenal available for treating Leishmania infections, as well as recent advances from research on plants and synthetic compounds as source drugs for treating the disease, and highlights some biopharmaceutical technologies in the design of the delivery strategy.
Journal ArticleDOI
Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles.
TL;DR: The review focuses on the biological and biopharmaceutical issues to be considered in the design of delivery strategy for treating parasitic infections and describes the role of the colloidal carriers liposomes, polymeric nanoparticles, lipid nanoparticles in optimizing the delivery of anti-malarial, anti-leishmanial and anti-trypanosomial agents.
References
More filters
Journal ArticleDOI
Drug development for neglected diseases: a deficient market and a public-health policy failure
Patrice Trouiller,Piero Olliaro,Piero Olliaro,Els Torreele,James Orbinski,James Orbinski,Richard Laing,Richard Laing,Nathan Ford +8 more
TL;DR: It is found that, of 1393 new chemical entities marketed between 1975 and 1999, only 16 were for tropical diseases and tuberculosis, and there is a 13-fold greater chance of a drug being brought to market for central-nervous-system disorders or cancer than for a neglected disease.
Journal ArticleDOI
Comparative genomics of trypanosomatid parasitic protozoa.
Najib M. El-Sayed,Peter J. Myler,Peter J. Myler,Gaëlle Blandin,Matthew Berriman,Jonathan Crabtree,Gautam Aggarwal,Elisabet Caler,Hubert Renauld,Elizabeth A. Worthey,Christiane Hertz-Fowler,Elodie Ghedin,Christopher S. Peacock,Daniella Castanheira Bartholomeu,Brian J. Haas,Anh Nhi Tran,Jennifer R. Wortman,U. Cecilia M. Alsmark,Samuel V. Angiuoli,Atashi Anupama,Jonathan H. Badger,Frédéric Bringaud,Eithon Cadag,Jane M. Carlton,Gustavo C. Cerqueira,Todd Creasy,Arthur L. Delcher,Appolinaire Djikeng,T. Martin Embley,Christopher R. Hauser,Alasdair Ivens,Sarah K. Kummerfeld,José B. Pereira-Leal,Daniel Nilsson,Jeremy Peterson,Steven L. Salzberg,Joshua Shallom,Joana C. Silva,Jaideep P. Sundaram,Scott J. Westenberger,Owen White,Sara E. Melville,John E. Donelson,Björn Andersson,Kenneth Stuart,Kenneth Stuart,Neil Hall +46 more
TL;DR: No evidence that these species are descended from an ancestor that contained a photosynthetic endosymbiont is revealed, and a conserved core proteome of about 6200 genes in large syntenic polycistronic gene clusters is revealed.
Journal ArticleDOI
Oral Miltefosine for Indian Visceral Leishmaniasis
Shyam Sundar,T. K. Jha,Thakur Cp,Juergen Engel,Herbert Sindermann,Christina Fischer,Klaus Junge,Anthony Bryceson,Jonathan Berman +8 more
TL;DR: Oral miltefosine is an effective and safe treatment for Indian visceral leishmaniasis and may also be helpful in regions where parasites are resistant to current agents.
Journal ArticleDOI
Drug resistance in Indian visceral leishmaniasis.
TL;DR: Despite several disadvantages, amphotericin B is the only drug available for use in these areas and should be used as first‐line drug instead of Sbv, and the new oral antileishmanial drug miltefosine is likely to be the first-line drug in future.
Journal ArticleDOI
Specific chemotherapy of Chagas disease: controversies and advances.
Julio A. Urbina,Roberto Docampo +1 more
TL;DR: Promising approaches include interference with trypanothione synthesis and redox metabolism, in addition to inhibition of purine salvage, dihydrofolate reductase, phospholipid biosynthesis, and protein prenylation and acylation.
Related Papers (5)
Leishmaniasis– current chemotherapy and recent advances in the search for novel drugs
Simon L. Croft,Graham H. Coombs +1 more